NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology platform company whose news flow centers on clinical data readouts, strategic collaborations, and corporate milestones. The company highlights a pipeline led by the bispecific antibodies givastomig and ragistomig, the anti-CD73 antibody uliledlimab, and the bifunctional biologic VIS-101.
News updates frequently cover oncology clinical trial results. For givastomig, NovaBridge has reported Phase 1b combination data in first-line HER2-negative metastatic gastric cancer, where the Claudin 18.2 x 4-1BB bispecific antibody is combined with nivolumab and chemotherapy. Releases describe objective response rates, progression-free survival measures, safety profiles, and biomarker analyses across CLDN18.2 and PD-L1 expression levels. For ragistomig, the company publishes Phase 1 monotherapy and dose expansion data in heavily pre-treated solid tumor patients, including comparisons of different dosing schedules and their safety and disease control rates.
Investors can also expect ophthalmology program updates through NovaBridge’s Visara subsidiary, particularly around VIS-101 in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Announcements have included leadership appointments at Visara and licensing arrangements with Everest Medicines for VIS-101 in Greater China and certain Asian markets.
Corporate and capital markets developments are another regular theme. NovaBridge has issued news on its transition from I-Mab to NovaBridge Biosciences, the change of its Nasdaq ticker to NBP, and its inclusion in the Nasdaq Biotech Index. The company also communicates its intention to pursue a dual listing on Nasdaq and the Hong Kong Stock Exchange.
By following the NBP news feed, readers can track clinical progress across multiple programs, updates on global partnerships, and key branding and listing milestones that shape NovaBridge’s evolution as a biotechnology platform.
NovaBridge Biosciences (NBP) subsidiary Visara entered an exclusive license agreement with Wuhan Hiteck Biological Pharma to develop and commercialize VIS-102.
The rights cover the world excluding Greater China. VIS-102, an investigational nerve growth factor therapy for neurotrophic keratitis, becomes Visara's second clinical-stage program, extending its pipeline beyond retinal disease. Hiteck will receive an upfront payment, potential milestone payments and tiered royalties on net sales.
In Chinese subjects with severe disease, the Phase 1b highest-dose cohort achieved 50% complete corneal healing after eight weeks; vehicle controls achieved 14% at Week 4. After switching to active treatment, controls achieved 43% healing following four weeks of VIS-102. Treatment-related ocular adverse events were mild, with no related withdrawals or discontinuations. An expansion phase will evaluate eight-week regimens given six or three times daily.
Hiteck (SZSE: 300683) entered an exclusive license agreement with Visara to develop and commercialize investigational eye drop HT006.2.2 outside Greater China. Visara, a majority-owned subsidiary of NovaBridge Biosciences (NASDAQ: NBP), plans to develop the neurotrophic keratitis treatment as VIS-102. Hiteck retains all rights in Greater China and will receive an upfront payment, with eligibility for milestone payments and tiered royalties on net sales.
In a Chinese Phase 1b study in severe neurotrophic keratitis, 50% of subjects in the highest-dose cohort achieved complete corneal healing after eight weeks. The vehicle control group recorded 14% healing at Week 4 before crossing to active treatment. Treatment-related ocular adverse events were all mild; none caused withdrawal or discontinuation.
NovaBridge Biosciences (NASDAQ: NBP) will present updated Phase 1b givastomig combination-study results at ESMO Congress on October 25, 2026.
The study evaluates givastomig with nivolumab and mFOLFOX6 chemotherapy in previously untreated participants with HER2-negative, CLDN18.2-positive and PD-L1-positive gastroesophageal adenocarcinoma that is locally advanced, unresectable or metastatic. NovaBridge expects the presentation to provide a more mature view of observed safety, efficacy and durability. Samuel J. Klempner will present poster 2945P at the congress in Madrid. No numerical safety or efficacy results were disclosed in this announcement.
NovaBridge Biosciences (NBP) appointed Martin Dewhurst as an independent director on its Board on September 8, 2026.
Dewhurst will also serve on NovaBridge’s Audit Committee and Compensation Committee, effective immediately. He brings more than 30 years of leadership, governance, and strategic advisory experience across biotech, biopharma, medical devices, health tech, and healthcare investment, including over three decades at McKinsey & Company, where he co-led the Global Life Sciences Practice and co-founded the McKinsey Health Institute. His appointment follows the departure of independent director Liu Xin from the Board. Dewhurst currently holds multiple board and advisory roles in healthcare companies and investment firms.
NovaBridge Biosciences (Nasdaq: NBP) announced that CEO Srishti Gupta will present at two investor conferences in September 2026. She will join fireside chats and one-on-one meetings at the Cantor 2026 Global Healthcare Conference on September 10, 2026 at 1:00 PM ET and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 at 9:30 AM ET. Webcasts of both sessions will be available on NovaBridge’s News & Events webpage for 90 days.
NovaBridge (Nasdaq: NBP) reported first half 2026 results, highlighting pipeline progress in oncology and ophthalmology and leadership changes. As of June 30, 2026, cash, cash equivalents, short-term investments and equity investments at fair value totaled $215.9 million, which the company believes can fund multiple milestones, including a planned Phase 3 interim read-out for givastomig in 2028.
Givastomig delivered positive Phase 1b data in first-line metastatic gastric cancer and is in a global Phase 2 study, with potential Phase 3 initiation as early as year-end 2026 under an Accelerated Approval Pathway. VIS-101 showed positive Phase 2a data in nAMD, with Phase 2b initiation in 2H 2026 and a global Phase 3 in 2027. R&D expenses rose to $14.3 million and administrative expenses to $26.4 million, driving a $37.9 million net loss for the period.
NovaBridge Biosciences (Nasdaq: NBP) announced it will host a webcast on Thursday, August 20, 2026, at 9:00 AM ET / 9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026.
Investors can access the live and archived webcast via the Upcoming Events section of the Investors page on the NovaBridge website, with separate links for China and other locations. A replay will be available for at least 30 days after the event.
NovaBridge is a global biotechnology company with clinical programs in oncology and ophthalmology, led by candidates givastomig and VIS-101, and focuses on advancing differentiated therapeutic opportunities through tailored development, financing, and partnering strategies.
NovaBridge Biosciences (Nasdaq: NBP) will hold its annual general meeting of shareholders on September 8, 2026 at 10:00 a.m. Shanghai time at its Shanghai office, AIA Tower, 38F, No. 866 Dongchangzhi Road. Shareholders of record as of July 27, 2026 may attend and vote.
Holders of ADSs as of the same date must vote through Citibank, the depositary. The notice, proxy form, and the company’s Form 20-F Annual Report for 2025, including audited financials, are available on NovaBridge’s website and the SEC website.
NovaBridge Biosciences (Nasdaq:NBP) appointed Srishti Gupta, MD MPP as Chief Executive Officer and board member, effective July 1, 2026. Outgoing CEO Xi-Yong (Sean) Fu, PhD MBA will step down and support the company in an advisory role during the transition.
Dr. Gupta, an experienced CEO with over two decades in biopharmaceuticals, global health, and strategy, will focus on advancing givastomig and VIS-101 toward registration, growing the ophthalmology franchise under Visara, and building strategic partnerships to extend NovaBridge’s medicines globally.
NovaBridge Biosciences (Nasdaq: NBP) received FDA Fast Track Designation for bispecific antibody givastomig plus nivolumab and chemotherapy in previously untreated HER2-negative advanced or metastatic gastric/gastroesophageal adenocarcinoma that is CLDN18.2 and PD-L1 positive.
Phase 1b data showed efficacy and tolerability, with a registrational Phase 3 trial expected to start as early as Q4 2026.